Glenmark Pharmaceuticals' shares surged 10% to an all-time high of ₹2,094 following the announcement of an exclusive ...

Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer ...

Ichnos Glenmark Innovation subsidiary IGI Therapeutics has signed an exclusive licensing agreement with AbbVie for ISB 2001, ...

The deal hands AbbVie a drug that’s shown early promise in multiple myeloma and may be useful treating other cancers and ...

AbbVie has placed a high price on that potential, coughing up $700 million for a phase 1 candidate and offering up to $1.225 ...

FDA designates MB-101 CAR T-cell therapy for glioblastoma, highlighting its potential in treating aggressive brain tumors ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the most undervalued large cap stocks to buy according to analysts. On ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Mustang Bio makes the NASDAQ top percentage gainers list on FDA news, currently trading at $3.56. up $2.37, gaining 199% on volume of over 152 Million shares as of this report. The stock has a day's ...

The FDA granted orphan drug designation to a CAR T-cell therapy for recurrent glioblastoma and high-grade astrocytomas.

Investing.com -- Mustang Bio Inc (NASDAQ: MBIO) stock surged over 78% after the U.S. Food and Drug Administration granted orphan drug designation to its MB-101 treatment for recurrent diffuse and ...

Detailed price information for Mustang Bio Inc (MBIO-Q) from The Globe and Mail including charting and trades.